BACKGROUND: Left ventricular global longitudinal strain (LVGLS) can detect early phases of LV systolic dysfunction, but its application has not been studied in Ebstein anomaly. We hypothesized that LVGLS can detect early phases of LV systolic dysfunction and that patients with occult LV systolic dysfunction will have worse hemodynamics, end-organ dysfunction, and suboptimal postoperative LV reverse remodeling after tricuspid valve surgery in comparison to patients with normal LV systolic function. METHODS: In this retrospective cohort study, 371 Ebstein patients that underwent tricuspid valve surgery were divided into 3 groups: normal LV systolic function (normal LVGLS and LV ejection fraction; n=244, 77%), occult LV systolic dysfunction (abnormal LVGLS with normal LV ejection fraction; n=44, 14%), and overt LV systolic dysfunction (abnormal LVGLS and LV ejection fraction; n=27, 9%). RESULTS: Compared with the normal LV function group, the occult group had smaller LV volume and cardiac output (2.1±0.4 versus 2.9±0.6 L/min per m2, P<0.001), worse end-organ dysfunction (glomerular filtration rate, 78±14 versus 91±18 mL/min per 1.73 m2, P=0.01), and suboptimal postoperative LV reverse remodeling. Although both the occult and overt groups had a similar degree of end-organ dysfunction (glomerular filtration rate, 78±14 versus 82±16 mL/min per 1.73 m2, P=0.3), the occult group was less likely to be on heart failure therapy (48% versus 96%, P<0.001). CONCLUSIONS: Abnormal LVGLS was associated with suboptimal postoperative LV reverse remodeling. These data suggest that LVGLS can potentially be used for risk stratification and provides a foundation for further studies to determine whether optimal heart failure therapy or tricuspid valve intervention can improve outcomes for LV systolic dysfunction in patients with Ebstein anomaly.
BACKGROUND: Left ventricular global longitudinal strain (LVGLS) can detect early phases of LV systolic dysfunction, but its application has not been studied in Ebstein anomaly. We hypothesized that LVGLS can detect early phases of LV systolic dysfunction and that patients with occult LV systolic dysfunction will have worse hemodynamics, end-organ dysfunction, and suboptimal postoperative LV reverse remodeling after tricuspid valve surgery in comparison to patients with normal LV systolic function. METHODS: In this retrospective cohort study, 371 Ebstein patients that underwent tricuspid valve surgery were divided into 3 groups: normal LV systolic function (normal LVGLS and LV ejection fraction; n=244, 77%), occult LV systolic dysfunction (abnormal LVGLS with normal LV ejection fraction; n=44, 14%), and overt LV systolic dysfunction (abnormal LVGLS and LV ejection fraction; n=27, 9%). RESULTS: Compared with the normal LV function group, the occult group had smaller LV volume and cardiac output (2.1±0.4 versus 2.9±0.6 L/min per m2, P<0.001), worse end-organ dysfunction (glomerular filtration rate, 78±14 versus 91±18 mL/min per 1.73 m2, P=0.01), and suboptimal postoperative LV reverse remodeling. Although both the occult and overt groups had a similar degree of end-organ dysfunction (glomerular filtration rate, 78±14 versus 82±16 mL/min per 1.73 m2, P=0.3), the occult group was less likely to be on heart failure therapy (48% versus 96%, P<0.001). CONCLUSIONS: Abnormal LVGLS was associated with suboptimal postoperative LV reverse remodeling. These data suggest that LVGLS can potentially be used for risk stratification and provides a foundation for further studies to determine whether optimal heart failure therapy or tricuspid valve intervention can improve outcomes for LV systolic dysfunction in patients with Ebstein anomaly.
Authors: Clyde W Yancy; Mariell Jessup; Biykem Bozkurt; Javed Butler; Donald E Casey; Mark H Drazner; Gregg C Fonarow; Stephen A Geraci; Tamara Horwich; James L Januzzi; Maryl R Johnson; Edward K Kasper; Wayne C Levy; Frederick A Masoudi; Patrick E McBride; John J V McMurray; Judith E Mitchell; Pamela N Peterson; Barbara Riegel; Flora Sam; Lynne W Stevenson; W H Wilson Tang; Emily J Tsai; Bruce L Wilkoff Journal: Circulation Date: 2013-06-05 Impact factor: 29.690
Authors: Kimberly A Holst; Joseph A Dearani; Sameh Said; Roxann B Pike; Heidi M Connolly; Bryan C Cannon; Kristen L Sessions; Megan M O'Byrne; Patrick W O'Leary Journal: Ann Thorac Surg Date: 2017-11-24 Impact factor: 4.330
Authors: Patrick J Goleski; Florence H Sheehan; Sylvia S M Chen; Philip J Kilner; Michael A Gatzoulis Journal: Int J Cardiol Date: 2013-12-27 Impact factor: 4.164
Authors: M Packer; A J Coats; M B Fowler; H A Katus; H Krum; P Mohacsi; J L Rouleau; M Tendera; A Castaigne; E B Roecker; M K Schultz; D L DeMets Journal: N Engl J Med Date: 2001-05-31 Impact factor: 91.245
Authors: Attila Kovács; Attila Oláh; Árpád Lux; Csaba Mátyás; Balázs Tamás Németh; Dalma Kellermayer; Mihály Ruppert; Marianna Török; Lilla Szabó; Anna Meltzer; Alexandra Assabiny; Ede Birtalan; Béla Merkely; Tamás Radovits Journal: Am J Physiol Heart Circ Physiol Date: 2015-01-23 Impact factor: 4.733
Authors: Morgan L Brown; Joseph A Dearani; Gordon K Danielson; Frank Cetta; Heidi M Connolly; Carole A Warnes; Zhuo Li; David O Hodge; David J Driscoll Journal: J Thorac Cardiovasc Surg Date: 2008-05 Impact factor: 5.209
Authors: Morgan L Brown; Joseph A Dearani; Gordon K Danielson; Frank Cetta; Heidi M Connolly; Carole A Warnes; Zhuo Li; David O Hodge; David J Driscoll Journal: J Am Coll Cardiol Date: 2008-08-05 Impact factor: 24.094
Authors: Tarek Alsaied; Adam B Christopher; Jose Da Silva; Aditi Gupta; Victor O Morell; Lizabeth Lanford; Jacqueline G Weinberg; Brian Feingold; Thomas Seery; Arvind Hoskoppal; Bryan H Goldstein; Jennifer A Johnson; Laura J Olivieri; Luciana De Fonseca Da Silva Journal: Pediatr Cardiol Date: 2022-09-23 Impact factor: 1.838